Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scienture Holdings, Inc.SCNX · Entity 7802 | Director · President & Co-CEO | September 19, 2024 | March 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scienture Holdings, Inc.
Report date September 19, 2024 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001SEC Table I · non-derivative | IndirectBy Srivatsav, LLC | 1,395,515 |
Last balance in matching sequence
After 2025-03-10 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-09-19 · Conversion · Acquired 1,357,538 · Balance 1,415,515 F1: These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date. F2: These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Row 2 · 2025-03-10 · Other · Disposed 20,000 · Balance 1,395,515 F3: These shares of Common Stock were transferred by Srivatsav to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Mani, and certain other parties thereto. F2: These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common Stock, par value $0.00001SEC Table I · non-derivative | Direct | 1,550,000 |
Ending reported balance
After 2026-02-20 transaction · row 5
3 source rows · reconciled sequenceRow 3 · 2025-04-14 · Grant · Acquired 750,000 · Balance 750,000 F4: These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026. Row 4 · 2025-10-01 · Grant · Acquired 300,000 · Balance 1,050,000 F5: These Restricted Shares vest in two equal annual installments beginning on October 1, 2026. Row 5 · 2026-02-20 · Grant · Acquired 500,000 · Balance 1,550,000 F6: On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date. |
| Series X Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Srivatsav, LLC | 0 |
Reported balance
After 2024-09-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-09-19 · Conversion · Disposed 1,357,538 · Balance 0 F1: These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date. F2: These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.
F2: These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3: These shares of Common Stock were transferred by Srivatsav to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Mani, and certain other parties thereto.
F4: These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026.
F5: These Restricted Shares vest in two equal annual installments beginning on October 1, 2026.
F6: On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Mar 12, 2026 21:32 UTC | Scienture Holdings, Inc. SCNX · Entity 7802 | GrantCommon Stock, par value $0.00001 | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009941 · ownership.xml · nonDerivative · entry 5 Narasimhan Mani · CIK 0002031317 · Director · President & Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550,000 F6 · shares: On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date. Read SEC document |
| October 01, 2025 Filed Mar 12, 2026 21:32 UTC | Scienture Holdings, Inc. SCNX · Entity 7802 | GrantCommon Stock, par value $0.00001 | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009941 · ownership.xml · nonDerivative · entry 4 Narasimhan Mani · CIK 0002031317 · Director · President & Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,000 F5 · shares: These Restricted Shares vest in two equal annual installments beginning on October 1, 2026. Read SEC document |
| April 14, 2025 Filed Mar 12, 2026 21:32 UTC | Scienture Holdings, Inc. SCNX · Entity 7802 | GrantCommon Stock, par value $0.00001 | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009941 · ownership.xml · nonDerivative · entry 3 Narasimhan Mani · CIK 0002031317 · Director · President & Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 F4 · shares: These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026. Read SEC document |
| March 10, 2025 Filed Mar 12, 2026 21:32 UTC | Scienture Holdings, Inc. SCNX · Entity 7802 | OtherCommon Stock, par value $0.00001 | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009941 · ownership.xml · nonDerivative · entry 2 Narasimhan Mani · CIK 0002031317 · Director · President & Co-CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Srivatsav, LLC Disclosed balance after: 1,395,515 F3 · shares: These shares of Common Stock were transferred by Srivatsav to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Mani, and certain other parties thereto. F3 · price: These shares of Common Stock were transferred by Srivatsav to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Mani, and certain other parties thereto. F2 · ownership.nature: These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2024 Filed Mar 12, 2026 21:32 UTC | Scienture Holdings, Inc. SCNX · Entity 7802 | ConversionSeries X Non-Voting Convertible Preferred Stock · Derivative | 1,357,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-009941 · ownership.xml · derivative · entry 6 Narasimhan Mani · CIK 0002031317 · Director · President & Co-CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Srivatsav, LLC Disclosed balance after: 0 Underlying: Common Stock, par value $0.00001 · 1,357,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date. F2 · ownership.nature: These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 19, 2024 Filed Mar 12, 2026 21:32 UTC | Scienture Holdings, Inc. SCNX · Entity 7802 | ConversionCommon Stock, par value $0.00001 | 1,357,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-009941 · ownership.xml · nonDerivative · entry 1 Narasimhan Mani · CIK 0002031317 · Director · President & Co-CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Srivatsav, LLC Disclosed balance after: 1,415,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date. F2 · ownership.nature: These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.